Publicacións en colaboración con investigadores/as de National Taiwan University Hospital (2)

2020

  1. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    Journal of Clinical Oncology

2018

  1. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer

    New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039